ClinicalIntelPulse

Live 402 challenge

Captured by the enrichment pass, not read just now. Prices can change — always read the 402 the endpoint answers with.

{
  "error": "X-PAYMENT header is required",
  "accepts": [
    {
      "asset": "0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913",
      "extra": {
        "name": "USD Coin",
        "version": "2"
      },
      "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
      "scheme": "exact",
      "network": "base",
      "mimeType": "application/json",
      "resource": "https://clinicalintelpulse.theaslangroupllc.com/api/clinical/deal-signal",
      "description": "Biotech M&A + licensing deal signal for clinical-stage drugs — Phase 2/3 assets most likely to be acquired or licensed, with acquisition targets, deal comps, transaction multiples and estimated deal values. Worldwide. For biotech-investing and BD agents.",
      "maxAmountRequired": "350000",
      "maxTimeoutSeconds": 300
    }
  ],
  "x402Version": 1
}

Accepts

The payment requirements as published to the catalog. Read the live 402 before paying — a price here is a claim, not a quote.

[
  {
    "asset": "0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913",
    "extra": {
      "name": "USD Coin",
      "version": "2"
    },
    "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
    "amount": "350000",
    "scheme": "exact",
    "network": "eip155:8453",
    "maxTimeoutSeconds": 300
  },
  {
    "asset": "EPjFWdd5AufqSSqeM2qN1xzybapC8G4wEGGkZwyTDt1v",
    "extra": {
      "feePayer": "D6ZhtNQ5nT9ZnTHUbqXZsTx5MH2rPFiBBggX4hY1WePM"
    },
    "payTo": "985iFjbnGQ3dJcwXnfRCMSrH4Jnc3kW1N6msR64B5KX1",
    "amount": "350000",
    "scheme": "exact",
    "network": "solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp",
    "maxTimeoutSeconds": 300
  }
]

Extensions

{
  "bazaar": {
    "info": {
      "input": {
        "type": "http",
        "method": "GET",
        "queryParams": {
          "lang": "en | es | fr | de | ja | zh | ko | pt | ar | hi (default: en)",
          "stage": "phase2 | phase3 | both (default: both)",
          "condition": "Disease area — e.g. \"Obesity\" | \"Cardiovascular\" | \"Oncology\" | \"Rare Neurological\" | \"Autoimmune\"",
          "deal_type": "acquisition | licensing | both (default: both)"
        }
      },
      "output": {
        "type": "json",
        "example": {
          "query_summary": {
            "as_of": "2026-06-07",
            "stage": "both",
            "condition": "Obesity",
            "deal_type": "both"
          },
          "market_context": {
            "approved_leaders": [
              "Semaglutide (Novo Nordisk — Wegovy)",
              "Tirzepatide (Lilly — Zepbound)"
            ],
            "big_pharma_strategic_need": "Roche, AstraZeneca, Pfizer, Amgen all need next-gen obesity assets. Roche acquired Carmot Therapeutics for $2.7B. AZ acquired Eccogene for obesity pipeline.",
            "total_addressable_market_usd_bn": 100
          },
          "recent_deal_comps": [
            {
              "deal": "Roche / Carmot Therapeutics",
              "year": 2023,
              "stage": "PHASE1/2",
              "mechanism": "GLP-1 peptide",
              "value_usd_bn": 2.7
            },
            {
              "deal": "AstraZeneca / Eccogene",
              "year": 2024,
              "stage": "PHASE2",
              "mechanism": "Small-molecule GLP-1",
              "value_usd_bn": 1.85
            },
            {
              "deal": "Amgen / ChemoCentryx",
              "year": 2022,
              "stage": "Approved",
              "mechanism": "C5aR1",
              "value_usd_bn": 3.7
            }
          ],
          "acquisition_targets": [
            {
              "asset": "Mazdutide (IBI362)",
              "risks": [
                "China geopolitical risk for IP transfer",
                "Phase 3 US/EU data needed before deal close"
              ],
              "stage": "PHASE3",
              "company": "Innovent Biologics (China)",
              "deal_comp": "Structure Day1 Biosciences (Pfizer) $1.25B + milestones — Phase 2 obesity asset. Mazdutide later-stage = premium.",
              "mechanism": "GLP-1/glucagon dual agonist",
              "probability": "High",
              "clinical_data": "Phase 3 China data strong — 14.5% body weight reduction at 52 weeks",
              "deal_rationale": "Ex-China rights available. Differentiated vs. semaglutide on muscle preservation. Lilly or Roche most likely acquirers.",
              "estimated_deal_value_usd_m": "800-2000"
            }
          ],
          "deal_timing_signals": "Obesity M&A is peak hot. Big pharma BD teams are actively searching — any Phase 2 readout with >10% weight loss and clean safety profile will attract inbound interest within 3-6 months of data release.",
          "licensing_opportunities": [
            {
              "asset": "CT-388 (dual GLP-1/GIP)",
              "notes": "Roche may sublicense ex-US rights to regional partners in Asia/LatAm",
              "company": "Carmot Therapeutics (acq. Roche)",
              "estimated_license_value_usd_m": "300-800"
            }
          ]
        }
      }
    },
    "schema": {
      "type": "object",
      "$schema": "https://json-schema.org/draft/2020-12/schema"
    }
  },
  "builder-code": {
    "info": {
      "a": "bc_gxy6qn5p"
    },
    "schema": {
      "type": "object",
      "$schema": "https://json-schema.org/draft/2020-12/schema",
      "properties": {
        "a": {
          "type": "string",
          "pattern": "^[a-z0-9_]{1,32}$",
          "description": "App builder code"
        },
        "s": {
          "type": "array",
          "items": {
            "type": "string",
            "pattern": "^[a-z0-9_]{1,32}$"
          },
          "description": "Service builder codes"
        },
        "w": {
          "type": "string",
          "pattern": "^[a-z0-9_]{1,32}$",
          "description": "Wallet builder code"
        }
      },
      "additionalProperties": false
    }
  }
}

Provenance

Seen in the source catalog

2026-07-01 04:21Z

Last indexed by Roundhouse

2026-07-30 16:00Z

Last enriched (probe, favicon, geo)

2026-09-11 06:45Z

x402 version

2

Max timeout

300s

Liveness probe

HTTP 402